Adalimumab therapy in rheumatic diseases

Speciality: Rheumatology

Description:

A warm welcome to all the medical professionals in this interesting session on Adalimumab therapy in rheumatic diseases
Adalimumab, a TNF (tumor necrosis factor) inhibitor, is widely used in the treatment of various rheumatic diseases such as rheumatoid arthritis (RA), psoriatic arthritis, ankylosing spondylitis, and juvenile idiopathic arthritis. By targeting TNF, a key driver of inflammation in these conditions, adalimumab helps reduce joint inflammation, alleviate pain, and slow disease progression. Clinical studies have shown significant improvements in joint function, quality of life, and long-term outcomes in patients treated with adalimumab.
In practice, adalimumab is often used in patients who do not respond adequately to traditional disease-modifying antirheumatic drugs (DMARDs). Its administration via subcutaneous injections allows patients to self-manage their treatment, offering convenience. However, like other biologics, adalimumab can increase the risk of infections, and regular monitoring is necessary. Despite the need for vigilance regarding side effects, adalimumab has become a cornerstone in managing chronic rheumatic diseases, providing relief and improving the quality of life for many patients.
Therefore, get an overall knowledge of adalimumab therapy in rheumatic diseases
 

See More Webinars @ Hidoc Webinars